ASH 2023 | Real-world efficacy & safety of teclistamab in patients with heavily pretreated R/R multiple myeloma

Danai Dima, MD, Cleveland Clinic, Cleveland, OH, discusses a multicentre retrospective study assessing the real-world safety and efficacy of teclistamab in heavily pretreated patients with relapsed/refractory (R/R) multiple myeloma (MM). Teclistamab was approved based on the MajesTEC-1 trial (NCT04557098); however, many patients in the clinic present with a range of high-risk features which would make them ineligible for this trial, meaning that a lack of data exists on the outcomes of the drug in a real-world patient population. Dr Dima highlights that the efficacy of teclistamab was relatively well maintained in the real-world population when comparing the overall response rate (ORR) to MajesTEC-1 data; however, progression-free survival (PFS) was lower. No new safety signals were determined in this cohort, with the frequency and severity of adverse events (AEs) mirroring the pivotal clinical trial. This study indicates that the efficacy and safety assessment of teclistamab in a real-world patient population is encouraging. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.